Estrogens are involved in development and maintenance of the female phenotype, germ cell maturation, and pregnancy. Sequential Maternal Screening, Part 2, Serum and Quad Screen (Second Trimester) Maternal, Serum in biochemical second trimester or cross-trimester screening for Down syndrome and trisomy 18 syndrome. while E3 possess only 20% of the E2 affinity for the estrogen receptor. E3 is derived largely through conversion of E2, and to a lesser degree from 16a-metabolites of E1. E2 and E1 can also be converted into each other, and both can be inactivated via hydroxylation and conjugation. During pregnancy E3 becomes the dominant estrogen. The fetal adrenal gland secretes dehydroepiandrosterone-sulfate (DHEAS), which is converted to E3 in the placenta and diffuses into the maternal circulation. The half-life of unconjugated E3 (uE3) in the maternal blood system is 20 to 30 minutes, since the maternal liver quickly conjugates E3 to make it more water soluble for urinary excretion. E3 levels increase throughout the course of pregnancy. Decreased second trimester uE3 has been shown to be a marker for Down and trisomy-18 syndromes. It also is low in cases of gross neural tube defects such as anencephaly. Based on these observations, uE3 has become a part of multiple marker prenatal biochemical screening, together with alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and inhibin-A measurements (QUAD / Quad Screen (Second Trimester) Maternal, Serum). Low levels of uE3 also have been associated with pregnancy loss, Smith-Lemli-Opitz syndrome (defect in cholesterol biosynthesis), X-linked ichthyosis and contiguous gene syndrome (placental sulfatase deficiency disorders), aromatase deficiency, and primary or secondary fetal adrenal insufficiency. High levels of uE3, or sudden increases in maternal uE3 levels, are a marker of pending labor. The rise occurs approximately 4 weeks before onset of labor. Since uE3 has been shown to be more accurate than clinical assessment in predicting labor onset, there is increasing interest in its use in assessment of preterm labor risk.
No special preparation is needed for E3. Inform your doctor if you are on any medications or have any underlying medical conditions or allergies before undergoing E3. Your doctor depending on your condition will give specific instructions.
|MALE||All age groups||< 0.18 ng/ml|
|FEMALE||All age groups||< 0.21 ng/ml (Non pregnant female) and < 14.60ng/ml (Pregnancy third trimester)|